0LKB.LSE Vanda Pharmaceuticals Inc.
- Market cap
- -
- P/E
- 11.7x
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 0LKB.LSE undervalued?
Graham numberThe Graham number of Vanda Pharmaceuticals Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vanda Pharmaceuticals Inc. fundamental analysis
No fundamental analysis for Vanda Pharmaceuticals Inc. yet.
Vanda Pharmaceuticals Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; …
Full company profileFinancial statements of Vanda Pharmaceuticals Inc. are not available yet.
Vanda Pharmaceuticals Inc. dividends
Vanda Pharmaceuticals Inc. has not paid dividends in the last 4 fiscal years.
Who owns Vanda Pharmaceuticals Inc.
- Insiders 6.78%
- Institutions 87.61%
- Public & others 5.62%
- Free float 46.8M
Vanda Pharmaceuticals Inc. company profile
- Company name
- Vanda Pharmaceuticals Inc.
- Ticker
- 0LKB.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 533
- Fiscal year end
- December
- Address
- 2200 Pennsylvania Avenue NW, Washington, DC, United States, 20037
- Phone
- 202 734 3400
- Website
- vandapharma.com
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Vanda Pharmaceuticals Inc. management
7- Dr. Mihael H. Polymeropoulos M.D.Founder, President, CEO & Chairman of The Board · born 1960
- Mr. Kevin Patrick MoranSenior VP, CFO & Treasurer · born 1984
- Mr. Joakim WijkstromSenior VP & Chief Marketing Officer · born 1966
- Mr. Gunther BirznieksSenior Vice President of Business Development · born 1969
- Mr. Daniel Patrick McGuireSenior VP, General Counsel & Secretary
- Mr. Scott L. HowellChief People Officer · born 1975
- Mr. Christos Polymeropoulos M.D.Senior Vice President & Medical Director